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Abstract
Estrogen receptor alpha (ERa), a ligand-dependent transcription factor, mediates the expression of its target genes by
interacting with corepressors and coactivators. Since the first cloning of SRC1, more than 280 nuclear receptor cofactors
have been identified, which orchestrate target gene transcription. Aberrant activity of ER or its accessory proteins results in
a number of diseases including breast cancer. Here we identified SFR1, a protein involved in DNA homologous
recombination, as a novel binding partner of ERa. Initially isolated in a yeast two-hybrid screen, the interaction of SFR1 and
ERa was confirmed in vivo by immunoprecipitation and mammalian one-hybrid assays. SFR1 co-localized with ERa in the
nucleus, potentiated ER’s ligand-dependent and ligand-independent transcriptional activity, and occupied the ER binding
sites of its target gene promoters. Knockdown of SFR1 diminished ER’s transcriptional activity. Manipulating SFR1
expression by knockdown and overexpression revealed a role for SFR1 in ER-dependent and -independent cancer cell
proliferation. SFR1 differs from SRC1 by the lack of an intrinsic activation function. Taken together, we propose that SFR1 is a
novel transcriptional modulator for ERa and a potential target in breast cancer therapy.
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Introduction
Estrogen signaling is mediated by two nuclear receptors, ERa
and ERb, which regulate a broad range of biological processes
(Reviewed in [1,2,3]). Like other nuclear hormone receptors, ERa
contains an N-terminal transactivation domain (AF1), a DNA
binding domain, a hinge region and a ligand binding domain
overlapping with the second transactivation domain (AF2). In the
absence of estradiol, ERa is normally present in the nucleus as
complex with heat shock proteins. Upon binding to estradiol, heat
shock proteins are released, and ERa undergoes conformational
changes, dimerizes and binds to the estrogen receptor responsive
elements (EREs) of the target genes. This initiates recruitment of a
number of transcriptional accessory proteins known as coactiva-
tors. The complex formation on the ERE facilitates the initiation
of target gene transcription in responsive tissues to promote
growth and proliferation [4].
In the absence of ligands, ERa (henceforth referred to as ER or
ERa) is bound by corepressors including N-CoR and SMRT [5],
through the corepressor’s CoRNR box motifs (LXXIXXXL) [6].
Ligand binding promotes a conformational change in ER most
notably in the helix 12 region. Subsequently, a binding pocket,
composed of helices 3, 4, 5 and the re-folded helix 12, is generated
to attract the LXXLL motifs (NR-boxes) of coactivators [7,8].
Nuclear receptor coactivators contribute to ERa-dependent
gene transcription in different fashions, including acetylating and
methylating histone tails, remodeling chromatin structure, recruit-
ing and modifying other coactivators, and bridging the general
transcription machinery with the nuclear receptors (reviewed in
[4,9]). Thus far, six groups of nuclear receptor coactivators have
been characterized, including: i) p160 family coactivators (SRC1,
SRC2/TIF2 and SRC3/AIB1), which directly bind to liganded
ER and recruit additional coactivators such as CBP/p300 and
CARM1 [10]; ii) CBP/p300 family members, acetylating p160
coactivators and histones, are responsible for the quick dispersal of
the coactivator complex [11,12]; iii) DRIP205/TRAP220/MED1,
which resides in the human mediator complex, thus anchoring the
general transcription machinery on the liganded nuclear receptors
[13]; iv) subunits of the SWI/SNF chromatin remodeling
complexes, including BAF57, Brm and Brg-1 [14], which help
to remodel the chromatin to increase the accessibility for
transcriptional factors/cofactors; v) non-p160 family proteins,
including some co-factors, such as RIP140, TIF1 and ARA70,
which can function as coactivators or corepressors depending on
the promoter and receptor contexts [4]; and vi) the so-called
secondary coactivators, including CoCoA and GAC63, which
bind to p160 family members but do not directly interact with
NRs [15,16].
The classical corepressors and coactivators bind to ER in the
strict ligand-independent and ligand-dependent manners. In this
work, we considered the possibility of the existence of novel ER-
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interacting proteins that may bind to ER in manners different
from that of classic corepressors and coactivators. To this end, an
unbiased yeast two-hybrid screen was conducted to identify novel
ER-interacting proteins, utilizing the CDEF domains of human
ERa as bait, both in the absence and presence of ER ligands. We
identified SFR1, a subunit of the Swi5-SFR1 (Mei5) complex
involved in DNA recombination and repair [17,18,19], as a novel
binding partner of ERa. SFR1 enhances ER’s ligand-independent
and ligand-dependent transcriptional activity and also promotes
breast cancer cell proliferation. SFR1, however, does not harbor
an intrinsic activation function and shares no homology with
known coactivators. We propose that SFR1 is a unique
transcriptional modulator of ER that can facilitate both ligand-
independent and ligand-dependent transcription. Importantly, our
results also categorize SFR1 into the group of proteins that
regulate both transcription and DNA repair.
Results
Yeast Two-hybrid Screen Identifies SFR1 Protein as an
ERa-interacting Partner
To identify novel co-factors of ERa, a yeast two-hybrid screen
was performed using a human mammary gland cDNA library with
ERa CDEF domain as the bait in the presence and absence of
estrogen. A number of known and novel proteins were identified,
including the p160 family member SRC1 [10] and the transcrip-
tion factor Stat3 [20]. We focused on a novel protein coded by a
gene on chromosome 10q25.1 (designated C10ORF78, accession
no. NM_001002759). Coincidently, another group recently
identified C10ORF78 as the human counterpart of yeast SFR1
(Mei1), a protein in the DNA homologous recombination pathway
[17]. Although there are three putative isoforms named SFR1-A, -
B, and -C based on the length of the predicted proteins, the longest
isoform, which codes 307aa, should represent the true transcript in
the cells (Figure S1A). Thus, western blot analysis showed a
consistent 37 kDa band of FLAG-SFR1 protein across multiple
cell types (Figure 1A). In addition, an independent study showed
that mouse SFR1 is a 303 amino acid protein [18]. The deduced
SFR1 protein is conserved in vertebrates, including mammals,
chicken, zebra fish and Xenopus (Figure S1). From amino acid
67–307, about 74% of amino acids are identical among human,
chimpanzee, monkey and dog. About 76% of amino acids are
conserved among all 5 mammalian species (Figure S1B).
The sequence of SFR1 reflects its unique role as a nuclear
receptor coregulator. At the conserved C-terminal region, SFR1
contains sequences (WXXWXXXW, W; hydrophobic amino acids)
similar to the CoRNR-box of corepressors and another sequence
similar to the NR-box (WXXWW, W; hydrophobic amino acids) of
coactivators (Figure S1A-B). Supporting the notion that these
motifs might mediate the interaction of SFR1 with nuclear
receptors and, hence, carry functional importance [8], they are
completely conserved among the different mammal species of
SFR1 proteins. SFR1 also contains a putative coiled-coil region.
Coiled-coil domains mediating protein-protein and/or protein-
DNA interactions have been found in nuclear receptor coactiva-
tors [21,22]. For example, CoCo-A, a secondary coactivator
containing a coiled-coil domain, was found to enhance ER and
AHR transcriptional regulatory activity [16]. Finally, although a
nuclear localization signal was not identified, several sub-cellular
localization prediction programs (WoLFPSORT, LOCtree and
SignalP3.0) predicted SFR1 as a non-secretory protein localized in
the cell nucleus, containing no DNA binding domain (data not
shown). Taken together, the domains within SFR1 are indicative
of hormone-receptor binding with nuclear function, consistent
with its nuclear receptor coregulator activity.
SFR1 mRNA is Expressed in Human Breast Cancer Cells
The information from GenBank indicated that human SFR1
mRNA was detected in multiple sex hormone-responsive tissues
including mammary gland, male and female reproductive
systems and prostate. Mouse SFR1 mRNA was detected in
the mammary tumor of MMTV-int1 transgenic mice, suggesting
possible involvement of SFR1 in mammary tumorigenesis. To
address the role of SFR1 in ER-positive breast cancer cells, we
examined the expression of SFR1 in several human cancer cell
lines. SFR1 mRNA was detected in ERa-positive MCF7 breast
cancer cells as well as Ishikawa endometrial adenocarcinoma
cells (Figure S1C). The SFR1 transcripts were also detected in
human skeletal muscle and fetal brain. The overlapping
expression of SFR1 with ERa is consistent with their functional
interaction in breast cancer cells.
SFR1 Interacts with ERa in Estrogen-sensitive Ishikawa
Cell Line Derived from Human Endometrial Cancer Cells
To confirm the interaction of SFR1 with ERa in mammalian
cells, the cDNA of SFR1 was cloned into p3XFLAG-CMV-7.1
mammalian expression vector and transfected into Ishikawa cells
(a cell line derived from human endometrial cancer). As predicted,
a 37 kDa band was detected with anti-FLAG M2 antibody
(Sigma), indicating that the fusion protein was expressed in
mammalian cells (see below Figure 1A). We then examined the
interaction between ERa and SFR1 proteins by reciprocal co-
immunoprecipitation (Co-IP) assays in Ishikawa cells. Consistent
with the yeast two-hybrid data, immunoprecipitation with both
anti-FLAG and anti-ERa antibody showed that ERa and SFR1
can pull each other down (Figure 1A), supporting the notion that
ER and SFR1 form a physical complex in vivo. To determine
whether SFR1 can bind to other nuclear receptors, Co-IP
experiments were performed with protein extracts from Ishikawa
cells co-transfected with androgen receptor (AR) and SFR1.
Similar to ER and SFR1 interaction, AR associated with SFR1
both in the absence and presence of dihydroxy-testosterone (DHT)
(data not shown).
Next, we tested whether the biochemical interaction between
ER and SFR1 can be recapitulated by the functional
mammalian one-hybrid assay. The SFR1 cDNA was subcloned
into the pM vector as bait. This fuses SFR1 with the first 147
amino acids of the Gal4 DNA-binding domain. The SRC1
cDNA fragment containing NR-boxes (SRC1-NR) known to
interact with ERa was similarly fused to Gal4-DBD and used as
a positive control. In the absence of ERa, neither SFR1 nor
SRC1-NR, as a Gal4-fusion protein, was capable of activating
luciferase reporter expression beyond the basal level. Co-
expression of ER allowed both Gal4-SFR1 and Gal4-SRC1-
NR to respond to estradiol (E2) stimulation (Figure 1B) by a
similar magnitude. These results are consistent with a function-
al, intracellular binding between ER and SFR1, in agreement
with the above coimmunoprecipitation results.
SFR1 Co-localized with ERa in Nucleus
Both SFR1 and ERa are nuclear proteins [17,18,19]. We
reasoned that if ERa and SFR1 physically interact, they should be
present at the same site in cell nuclei. To determine the
intracellular localization of SFR1, an immunofluorescence assay
was performed using HeLa cells transiently transfected with
FLAG-SFR1 and ER. As expected, transfected SFR1 was present
SFR1 Interacts with Estrogen Receptor Alpha
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in the nuclei of transfected cells (Figure 1C). No fluorescence signal
was detected in control IgG stained cells or in non-transfected cells
subjected to the anti-FLAG staining (data not shown). As
predicted, confocal immunofluorescence analysis revealed a strong
overlap in the expression of FLAG-SFR1 and EGFP-ERa in co-
transfected HeLa cells (Figure 1C). Notably, the co-localization
between SFR1 and ER was unaffected by E2 treatment (data not
shown), further underscoring that their interaction is ligand-
independent.
SFR1 Enhances ERa Transcriptional Activity in
Mammalian Cells
We have demonstrated that SFR1 interacts and colocalizes with
ERa in the cell nuclei. This nuclear interaction of SFR1 and ER
raised the question of whether SFR1 can modulate ERa’s
transcriptional activity. Therefore, in the following study, we
examined the effect of SFR1 and its truncated versions SFR1-B
and SFR1-C on ER-mediated transcriptional activity. Transient
co-transfection experiments were first conducted in Ishikawa cells
that express a low level of SFR1 mRNA, but do not have
detectable ER expression (as reflected in our following ERE-luc
reporter assays(the cells were originally ER positive, but lost ER
expression after several passages of culture). In the ERa-dependent
ERE-luc reporter assay, E2 treatment for a period of 12 hrs
resulted in a 3-fold activation, which was further increased in a
dose-dependent fashion by ectopic expression of SFR1 (Figure 2A).
Notably, we also observed a dose-dependent increase of ER
ligand-independent transcriptional activity in the presence of
SFR1. Similar enhancement was observed in COS-7 cells (data
not shown). We then tested whether the truncated forms of SFR1,
SFR1-B and SFR1-C, can enhance ERa transcriptional activity in
the reporter assay. Little transcriptional enhancement was
observed with SFR1-B and C, suggesting that the N-terminus of
SFR1 is important for its ER stimulatory function (Figure 2B).
Given that SFR1A can enhance ER transcriptional activity, we
asked whether SFR1 can modulate transcriptional activity of ERb
and AR which belong to the same nuclear receptor family. SFR1-
A but not SFR1-C enhanced AR transcriptional activity in the
presence and absence of DHT (Figure 2C). SFR1, however, did
not enhance ERb’s transcriptional activity in the similar assay
(Figure 2D), suggesting the transcriptional enhancement by SFR1
is nuclear hormone receptor-type specific.
SFR1 is Required for the Transcriptional Activity of
Endogenous ERa
SFR1 overexpression experiments described above indicated
that SFR1 is capable of enhancing both ligand-independent and
ligand-dependent transcriptional activity of ERa. The dose-
dependent effect of SFR1 indicates that SFR1 is a rate limiting
factor in the regulation of ER-dependent transcription. We also
Figure 1. SFR1-A interacts with ERa in mammalian cells and colocalized with ERa in cell nucleus. (A) FLAG-SFR1-A and ER were co-
transfected into Ishikawa cells. Co-IP experiments were performed with anti-ERa and anti-FLAG antibodies in Ishikawa cells in the presence and
absence of E2. (B) The interaction of ERa and SFR1-A was further analyzed with mammalian one-hybrid experiments in Ishikawa cells. pM vector, pM-
SFR1-A (SFR1-A) and pM-SRC1 were used as baits. Cells co-transfected with pM-SRC1 NR-box (SRC1) and pCMV5-ERa were used as positive control.
(n = 4, p,0.005) (C) The localization of SFR1A and ERa was evaluated with immunefluorescent staining. HeLa cells were co-transfected with FLAG-
SFR1-A and GFP-ERa. 24 hours after the transfection, cells were treated with E2 or vehicle overnight. The cells were fixed and stained with M2 anti-
FLAG antibody and Alexa Fluor 568 anti-mouse secondary antibody. Immunostained cells were photographed using a Zeiss LSM510 confocal
microscope with a 63X Zeiss objective. Scale bar = 20 mm. The error bars indicate standard deviations. * = P,0.05; ** = P,0.01; *** = P,0.005.
doi:10.1371/journal.pone.0068075.g001
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showed that ERa and SFR1 physically interact with each other in
the cell nucleus. As an extension to the above studies and to
further examine the physiological role of SFR1, the requirement of
SFR1 proteins for endogenous ER-mediated transcription was
examined using RNA interference to deplete endogenous SFR1 in
MCF7 cells. We validated the SFR1 siRNA by showing the
specific loss of FLAG-SFR1 expression on protein and mRNA
levels in SFR1 siRNA-transfected cells (Figure 3A and RT-PCR
data not shown). Depletion of SFR1 significantly impaired
estrogen-dependent 3xERE-luc reporter activity in MCF7 cells
both in the absence and presence of E2 treatment (Figure 3B).
GFP siRNA controls showed no effect on ERE-luc activity. This
result suggested that SFR1 is required for the optimal level of the
transcriptional activity of endogenous ERa.
We also tested whether SFR1 is required for endogenous AR
transcriptional activity in LNCaP cells. There was no significant
difference of AR transcriptional activity between the control
siRNA and SFR1 siRNA transfected cells in the presence of DHT
(Figure 3C).
We also asked whether SFR1 harbors an autonomous
transcriptional activation domain like that of SRC1. To test this,
we fused SFR1 and SFR1C to the heterologous DNA-binding
domain of GAL4 and transfected Gal4-SFR1 and Gal4-SFR1C
expression plasmid into Ishikawa cells and HeLa cells. The
transcription level of a co-transfected luciferase reporter contain-
ing four GAL4 binding sites at the promoter region was measured
by the luciferase assay. Using GAL4-SRC1-NR-box and ERa
one-hybrid as the positive control, neither SFR1 nor the truncated
SFR1-C can activate Gal4-luc reporter, indicating that SFR1 does
not contain an intrinsic transcriptional activation domain
(Figure 3D and data not shown).
Upon ligand stimulation, nuclear receptors including ER
recruit coactivators to endogenous target enhancers/promoters
in vivo to activate target gene transcription [23]. To test whether
SFR1 is involved in transcriptional activation of native ERa
target genes, we employed chromatin immunoprecipitation
(ChIP) assays to look for ERa-dependent recruitment of SFR1
to the ERa binding sites on pS2 and PR promoters in MCF7
breast cancer cells. To facilitate the detection of SFR1, we used
MCF7 cells expressing the FLAG-tagged SFR1. Control ChIP
assays using normal IgG produced very weak signal. In contrast,
SFR1 was detected on both pS2 and PR promoters in the
presence and absence of E2 treatment, but not on the outside
control region (Figure 3E). To determine the functional
significance of SRF1, SRF1 was depleted in MCF7 cells.
Depletion of SFR1 abated the expression of pS2 and PR upon
estrogen stimulation in MCF7 cells (Fig. S2). Two other ER
target genes, Cathepsin D and HSP27, however, did not show
significant change upon SFR1 knockdown in MCF7 cells,
indicating that SFR1 selectively regulates ER targets. Further-
more, the expression of non-ER target gene, beta-Actin was not
significantly changed. Together, these results show that SFR1 is
involved in ER-dependent regulation of target genes.
Figure 2. SFR1-A enhances ERa and AR transcriptional activity. The effects of SFR1 overexpression on ERa (A and B), ERb (D) and AR (C)
transcriptional activity were assessed by luciferase reporter assays. Ishikawa cells were co-transfected with nuclear receptors (ERa, ERb or AR), their
respective reporter genes (3xERE-luc and ARE-luc), and indicated amount of p3xFLAG-SFR1-A, p3xFLAG-SFR1-B (20 ng) or p3xFLAG-SFR1-C (20 ng)
(D). The cells were treated with vehicle or 1 nM E2 or DHT. Transcriptional activity was measured via luciferase assays at 12 hours and 24 hours after
ligand treatments. All luciferase reporter assays were conducted at 12 h after the ligand treatment unless it is indicated in the experiment. 20 ng of
SFR1A, SFR1B and SFR1C was transfected unless the amount of DNA was indicated in the figures. All experiments were performed multiple times with
triplicate samples. The error bars indicate standard deviations. * = P,0.05; ** = P,0.01; *** = P,0.005.
doi:10.1371/journal.pone.0068075.g002
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Figure 3. SFR1-A modulates ER transcription activity. (A) Western Blot was used to determine the effect of siRNA of SFR1 and control siRNA on
FLAG-SFR1 expression. MCF7 cells were co-transfected with FLAG-SFR1-A along with indicated control or SFR1 specific siRNA (30 nM). Twenty-four
hours after the transfection, cells were exposed to E2 (1 nM) or vehicle overnight. Lysates were harvested 48 hrs post-transfection and subjected to
Western Blot analysis with the indicated antibodies. (B) Luciferase reporter assay was performed in MCF7 cells to determine the impact of SFR1
knockdown on ER transcriptional activity. MCF7 cells were co-transfected with the indicated amount of SFR1 siRNA and 3xERE-luc reporter or 40 nM
scrambled siRNA and 3xERE-luc reporter. 24 hrs after the transfection, cells were treated with 1 nM E2 or vehicle for 24 h. Transcriptional activity was
measured via luciferase assay (n = 4). (C) Luciferase reporter assay was performed in LNCaP cells to determine the impact of SFR1 knockdown on AR
transcriptional activity. AR-positive LNCaP cells were co-transfected with the indicated amount of SFR1 siRNA and 3xARE-luc reporter or 40 nM
scrambled siRNA and 3xARE-luc reporter. 24 hrs after the transfection, cells were treated with 1 nM DHT or vehicle for 24 h. Transcriptional activity
was measured via luciferase assay. (D) Mammalian one-hybrid experiment was performed in Ishikawa cells to determine the intrinsic transcriptional
activity of SFR1. GAL4DBD (Vector), GAL4DBD-SFR1-A (SFR1-A), and GAL4DBD-SRC1NR-box plus ER (SRC1+ER) were co-transfected with Gal4-luc
reporter. The SRC1+ER one-hybrid was used as positive control. The level of transactivation was represented by luciferase activity (n = 4). (E) SFR1-A
was recruited to the promoter of endogenous ER target gene promoters. The in vivo binding of SFR1-A to pS2 and PR promoters was examined by
ChIP assay. FLAG-SFR1-A was transiently transfected into MCF7 cells. Soluble chromatin was prepared from the cells treated with 1 nM E2 (+) for 1 h
or vehicle (2) and immunoprecipitated with M2 antibody. Co-precipitated DNA was amplified using primers that flank the ERE in the pS2 promoter
region or half ERE and Sp1 site in the PR promoter. The presence of total pS2 and PR promoter DNA in the soluble chromatin prior to
immunoprecipitation was included as input. The error bars indicate standard deviations. * = P,0.05; ** = P,0.01; *** = P,0.005.
doi:10.1371/journal.pone.0068075.g003
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SFR1 Plays a Role in Estrogen-dependent and
Independent Cell Proliferation
It is well known that ERa mediates estrogen-stimulated cell
proliferation in mammary epithelium. Since SFR1 can enhance
ER transcriptional activity, we analyzed its roles in ERa-
dependent and -independent cell proliferation. Thymidine incor-
poration assays were utilized to monitor cell proliferation (as
reflected by DNA synthesis) under different conditions. The role of
SFR1 in ER-independent cell proliferation was determined in
SFR1-transfected HeLa cells. SFR1 significantly enhanced DNA
synthesis compared to mock-transfected HeLa cells (Fig. 4A).
Because SFR1 RNAi assays indicated that SFR1 is required for
ER-mediated transcription in MCF7 cells, we also determined
whether the estrogen-dependent growth of MCF7 cells is affected
by the depletion of SFR1. As expected, estrogen markedly
stimulated the growth of non-transfected (data not shown) and
scrambled (control) siRNA-transfected MCF7 cells. However,
SFR1 siRNA treatment completely abolished the estrogen-
dependent growth of MCF7 cells, suggesting that SFR1 proteins
are essential for ER-dependent cell proliferation and raising the
possibility that SFR1 could be a therapeutic target in breast cancer
(Figure 4C). Similarly, SFR1 knockdown in AR-positive LNCaP
cells also blocked AR-dependent cell proliferation (Figure 4B).
Furthermore and consistent with the thymidine incorporation
data, BrdU incorporation assays in MCF7 cells stably expressing
SFR1 shRNA and control luciferase shRNA also showed that
SFR1 is required for MCF7 cell proliferation (Figure 4D and E). In
SFR1 shRNA-transduced cells, cell apoptosis increased 3 fold
(from ,2% to .6%), and cell proliferation decreased 2.5-fold (a
significant decrease of cell numbers in S phase from ,23.3% to
10.4%). Although the effect of SFR1 knockdown on the cell
behavior is qualitatively similar to the effect of knockdown of
SRC1 (Fig. 4D), SFR1 shRNA partially released the growth
inhibition effect by SRC1 shRNA, indicating that SFR1 may
regulate MCF7 cell proliferation in an SRC1-independent fashion
(data not shown). Overall, these results indicated that SFR1 plays
roles in anti-apoptosis and cell proliferation in cancer cells.
Discussion
SFR1 is a Novel ER-interacting Protein and Functions as a
Unique Transcriptional Modulator of ER
We have identified the DNA recombination protein SFR1 as a
protein that directly binds and regulates ER’s transcriptional
activity by multiple complementary studies. First, SFR1 was
identified as an ER-interacting protein by the unbiased yeast two-
hybrid screen. Second, SFR1 co-localized with ERa in cell nuclei
and bound to ER in a ligand-independent fashion. Third, reporter
assays showed that the transcriptional regulatory activity of ERa
was enhanced by SFR1. Fourth, ChIP assays confirmed the direct
recruitment of SFR1 to the ER binding sites of two representative
target genes. Finally, not only was SFR1 involved in the
endogenous transcriptional activity of ERa, it also enhanced
ER-dependent cell proliferation.
Unlike some ER coactivators such as SRC1, no intrinsic
transcriptional activity was detected for SFR1. It also lacks
sequence homology with other known ER coactivators. These
findings, along with the ability of SFR1 to mediate ligand-
independent and ligand-dependent interactions with ER, led us to
propose that SFR1 functions as a unique transcriptional modu-
lator of ERa. The sequence of SFR1 carries features similar to that
of the CoRNR box of N-CoR/SMRT corepressors and that of the
NR box of coactivators. CoRNR boxes and NR boxes are known
to bind to the ligand-binding domain of nuclear receptors,
including ER. These motifs may thus serve as the structural basis
of the observed ligand-independent and ligand-dependent associ-
ations between SFR1 and ER, indicative of the unique co-
regulator function of SFR1. This idea is also consistent with the
fact that SFR1 was isolated from a human mammary gland cDNA
library on the basis of its interaction with the ERa CDEF domain
fragment.
Mechanism of ER Transcriptional Modulation by SFR1
Although a nuclear localization signal was not predicted for
SFR1, its function as a nuclear protein was confirmed by our
transient transfection and immunostaining experiments showing
SFR1 primarily resides in cell nuclei. SFR1 interacts with ER and
enhances both ligand-dependent and ligand-independent ERa
transcriptional activity (Figure 2A). However, the enhancement is
more robust at 12–16 h after the E2 treatment, suggesting a role
for SFR1 in dissociating the co-repressors bound to ERa and/or
facilitating the subsequent interaction of ERa with other
coactivators to assemble a functional transcriptional complex.
SFR1 may antagonize the function of some ligand-dependent
co-repressors, such as ligand-dependent corepressor (LCoR) and
repressor of estrogen receptor activity (REA), which bind ERa in
the presence of E2 [24,25,26]. LCoR inhibits ERa transcriptional
activity in a dose-dependent fashion by recruiting co-repressors
HDAC3 and CtBP to ERa. REA directly competes with p160
coactivators for binding to ER and can recruit class I and II
HDACs [27,28]. It remains to be determined whether SFR1 acts
similarly to CoCoA, a secondary coactivator that binds to GRIP1
with its coiled-coil domain and enhances nuclear receptor
transcriptional activity [16].
SFR1: a Potential New Link between Transcription and
DNA Repair and a Therapeutic Target for Breast Cancer
Some transcriptional cofactors can function both in the
regulation of transcription and DNA repair, such as the SWI/
SNF chromatin remodeling complex, the TFIIH general tran-
scription factor and the DNA-dependent protein kinase (DNA-
PK). Our results provide another example of such proteins.
Importantly, our work suggests that SFR1 may be specifically
involved in ER-dependent regulation of these processes. In this
context, Williamson showed that ER is required for an E2-induced
DNA double strand break, which is mediated by TopoII-beta [29].
Given that SFR1 binds to ER and that Swi5-SFR1 activates
RAD51 recombinase activity [17,18], it is possible that SFR1 may
play an important role in facilitating DNA homologous recombi-
nation repair following an ER-mediated DNA double strand
break. In a related scenario, recent studies have shown that
efficient transcriptional activation by ER requires transient
formation of a transcription-induced double strand DNA break
[30]. How this transiently-formed DNA break is repaired is not
known. Our work raises the intriguing possibility that SFR1 may
play a role in this transcription-coupled repairing process.
Like most NR cofactors, SFR1 is expressed in multiple cell types
and tissues. A role for SFR1 in the development of mammary
tumors is supported by the finding that the mRNA of SFR1
(GenBank: AAH24403) is expressed in mammary tumors of 5-
month-old MMTV-Wnt-1 transgenic mice. Further supporting
the involvement of SFR1 in the progression of ER-positive breast
cancer, we found that SFR1 is required for estrogen-dependent
MCF7 cell proliferation.
The effect we observed in proliferation assays is likely
contributed by an effect of SFR1 knockdown on cell cycle
progression in addition to its role in ER or AR mediated
transcription.
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While SFR1 may manifest its function in tumors by enhancing
ER’s transcriptional activity, given the involvement of SFR1 in the
regulation of DNA homologous recombination, it is also possible
that hormone receptors, such as ER, may impact the maintenance
of genome stability of cells. A further understanding of how SFR1
regulates ER’s transcriptional activity and how ER, through its
binding to SFR1, regulates DNA repair, may lead to the
identification of important targets that may be used to treat the
large number of ER-positive breast cancer patients.
Materials and Methods
Plasmids and Antibodies
The cDNA of SFR1 (GenBank accession # BC043256) was
purchased from Open Biosystem (Huntsville, AL). SFR1,SFR1-B
and SFR1-C cDNA were subcloned into p3XFLAG-7.1 expres-
sion vector (Sigma) for FLAG-tagged fusion protein and pM
(Clontech) for N-terminal Gal4 DBD fusion protein. pG5-luc
reporter construct was a kind gift from Dr. Cong Liu [31].
pSG5AR [32] and Gal4-SRC1-NRbox plasmid containing the
nuclear receptor interaction domain of SRC-1 (amino acids 595 to
780) [33] are kind gifts from Dr. Karen Knudsen’s lab. pCMV5-
ERa and p3XERE-luc reporter were provided by Dr. Benita
Katzenellenbogen (University of Illinois). Anti-FLAGM2 antibody
is from Sigma (Cat # F1804). Anti- ER H184 polyclonal antibody
is from Santa Cruz (Cat # sc-7207). Goat-anti-rabbit secondary
antibody (Cat# 31460) and goat-anti-mouse secondary antibodies
(Cat # 31430) are from Pierce. Mouse monoclonal anti-beta actin
antibody was from Sigma-Aldrich (Cat# A3853). Alexa Fluor 568
anti-mouse secondary was from Molecular Probes. FITC anti-
BrdU was from BD Bioscience (Cat # 347583).
Cell Culture and Transient Transfection
Ishikawa cells were grown in MEM (Fisher) with 10% fetal
bovine serum (Hyclone). HeLa and MCF7 cells were grown in
Figure 4. SFR1-A promotes cancer cell proliferation. Thymidine incorporation (A, B and C) and BrdU incorporation assays (D and E) were used
to examine the effect of SFR1 on cell proliferation. In thymidine incorporation assays, SFR1-A cDNA was transfected into HeLa cells (A) to determine
the impact of SFR1-A on hormone-independent cell proliferation. SFR1 siRNA (40 nM) or scrambled control, were transfected into LNCaP cells (B) and
MCF7 cells (C) to determine the effect of endogenous SFR1 protein on ER-dependent cell proliferation. To determine the long-term effect of loss of
SFR1 on cancer cell survival and proliferation, SFR1 knockdown MCF7 cell line was established by transducing MCF7 cells with lentivirus expressing
sh-SFR1. MCF7 cells expressing sh-SRC1 were used as positive control and MCF7 cells expressing sh-Luciferase (sh-Luc) were established as the
negative control. Sh-Luc, sh-SFR1 and sh-SRC1 cells were treated with BrdU for one hour at 37uC and harvested for antibody staining and FACS
analysis. FITC-anti-BrdU and 7AAD were used to distinguish cells in G0/G1 (P5), S (P4), G2/M (P6) and apoptosis phase (P7) in FACS analysis. The results
from the FACS analysis were analyzed and plotted with GraphPad Prism5 (E). N $3 in all experiments. * = P,0.05; ** = P,0.01; *** = P,0.005.
doi:10.1371/journal.pone.0068075.g004
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DMEM (Fisher) with 10% fetal bovine serum. The transfections
were carried out using SilentFect (Bio-Rad) or Lipofectamine 2000
(Invitrogen) for siRNA experiments, or with Fugene 6 (Roche) for
plasmids only, according to the manufacturers’ protocols. At 20 h
post-transfection, the cells were treated with specific ligands or
vehicle (ethanol) and were harvested after 18–24 h of incubation.
The cells were lysed in reporter lysis buffer (Promega) and assayed
for luciferase activity.
Chromatin Immunoprecipitation (ChIP)
ChIP assay was performed as previously described [23]. The
PCR primers used were as follows:
pS2 Forward: 59TTA GCT TAG GCC TAG ACG GAA
TGG; pS2 BACKWARD: GAC GAC ATG TGG TGA GGT
CAT CTT-39; pS2 OUTSIDE Forward: GGG GCT GTT TTC
CTG TGT TA-39; pS2 OUTSIDE BACKWARD: CAT TTG
GGC CTA TCT GGA TG-39; PR Forward: AAA GGG GAG
TCC AGT CGT CA-39;PR BACKWARD: CTG
GTCCTGCGTCTTTTCGT-39; PR OUTSIDE Forward:
GGA AGG TTA GAG GAA GAA TG-39; PR OUTSIDE
BACKWARD: CCT TTG CAC CTT TGT TGA GA-39.
Thymidine Incorporation
The assay was performed in LNCaP, HeLa and MCF7 cells as
previously described [34].
Reverse Transcription-PCR
For RT-PCR, total RNA was extracted and purified from cells
with Trizol (Invitrogen). Reverse transcription reactions were
carried out with the Retroscript kit (Ambion Cat # 1710),
following the manufacturer’s protocol. The resulting products
were subjected to PCR amplification with the following SFR1
primers: Forward: 59 GCT GAA AAA GCC AAA TTG GTG
39and Backward: 59 GCT GGC TAC AGC TTC TCC ACT 39.
RNA Interference
SFR1 siRNA (Dharmacon, Smart mix) or the SFR1 siRNA and
3XERE-luc reporter plasmid were introduced into MCF7 cells in
96-well or 12-well plates with SilentFect (Bio-Rad Cat # 170-
3360) or Lipofectamine 2000 (Invitrogen), respectively, following
the manufacturers’ protocols. Luciferase activities were assayed
with Luciferase Reporter Assay System (Promega).
Co-immunoprecipitation and Western Blot
Co-IP was performed according to the standard protocol
provided by Santa Cruz Biotechnology. Western blot was
performed according to the standard protocol provided by Sigma
for anti-FLAG M2 antibody. Nitrocellulose membrane was from
Bio-Rad (Cat # 162-0094). ECL kit is from Amersham
Biosciences (Cat # 1059250).
Immunofluorescence Assay
The immunofluorescence assays were performed according to
the standard protocol provided by Sigma for anti-FLAG M2
antibody.
Digital Photography
The pictures were photographed with a Zeiss LSM510 confocal
microscope (Carl Zeiss Co. NY) with 63X Zeiss objective lens.
Mammalian Hybrid Assays
Mammalian hybrid assays were performed as described [35],
except that a pM-SRC1 construct and pCMV5ERa were co-
transfected with 4XGal4-luc reporter into the Ishikawa cells. 16 h
after the transfection, the cells were treated with E2 for 24 h and
subjected to luciferase assay.
Sh-SFR1 Cell Line
MCF7 cells were transduced with pLK0.1-shSFR1 lentivirus
(Open Biosystem) and selected with 2 mg/ml puromycin until
colonies formed. The puromycin-resistant clones were selected
and expanded for different assays.
BrdU FACS Analysis
BrdU FACS analysis was performed as described [36] with
modifications. Prior to harvesting, cells were pulsed with BrdU for
1 hour. Cells were harvested by trypsinization and fixed in 70%
EtOH overnight at 4uC. Cell pellets were washed once with IFA
buffer (1x DPBS (Invitrogen), 4% FBS and 0.1% NaN3) and once
with IFA +0.5% Tween 20 prior to 1 hour incubation in FITC-
conjugated anti-BrdU (BD Pharmingen, 15 ml in 100 ml IFA) at
room temperature. Following incubation with antibody, cells were
washed once in IFA +0.5% Tween 20 and incubated with 7AAD
(BD Pharmingen). Cells were sorted by the FACS Canto flow
cytometer (BD). Histograms/scatter plots represent 20,000 gated
events. Cell cycle analysis was performed using FACS Diva
software. BrdU data are represented as percent of untreated
control.
Statistical Analysis
Data were analyzed and plotted using Prism 5.0 (GraphPad
Software). Statistical analysis was done with student t test for all
analyses. A value of P,.05 was considered significant.
Supporting Information
Figure S1 SFR1 protein structure and mRNA expression in
different tissues and cells. (A) Schematic representation of SFR1
protein isoforms. The NR-box-like, CoRNR-like and Coiled-coil
domains are indicated. Existence of the Coiled-coil domain was
predicted using ELM (www.expasy.com). (B) SFR1-A is conserved
in mammals. The multiple sequence alignment was performed
with EMBL-EBI ClustalW online software: http://www.ebi.ac.
uk/clustalw/. The homology of human SFR1-A with other
mammalian species is shown, with asterisks indicating positions
of identical amino acids, and dots and colons indicating the
positions of similar amino acids. CoRNR-like and LXXLI motifs
are indicted by rectangular boxes. (C) SFR1 mRNA is expressed in
various cell lines and tissues. Total RNA was isolated from cell
lines and subjected to RT-PCR with SFR1 primers. Human fetal
brain and skeletal muscle cDNA were analyzed as well. Lanes: 1.
Ishikawa cells; 2. C4-12 cells; 3. MCF7 cells; 4. Human Skeletal
Muscle cDNA; 5. Human Fetal Brain cDNA; 6. Mouse embryonic
fibroblast (MEF) cells. C4-12 and MCF7 are human breast cancer
cell lines. Ishikawa cells are human endometrial cancer cells. The
human SFR1 primers do not amplify mouse SFR1.
(TIF)
Figure S2 SFR1 is required for the expression of ER target
genes. qPCR was performed on RNA isolated from MCF7 cells
transfected with siSFR1 or siGFP (control). 24 hrs after the
transfection, cells were treated with E2 or vehicle overnight for
determining mRNA expression of Progesterone receptor (PR),pS2,
Cathepsin D (CTSD), Heat Shock Protein 27 (HSP27), and beta-
Actin. The expression of different genes was normalized to
GAPDH. All assays were performed in triplicates and error bars
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represent Standard Deviation (** = P,0.01, ns = no significance).
Data are representative of three independent experiments.
(TIF)
Author Contributions
Conceived and designed the experiments: YF JZ SK. Performed the
experiments: YF DS CG AG SK. Analyzed the data: YF DS AG JZ EJ SK.
Wrote the paper: YF DS JZ EJ SK. Conducted yeast two hybrid screen for
ER binding proteins: SP RK.
References
1. Deroo BJ, Korach KS (2006) Estrogen receptors and human disease. J Clin
Invest 116: 561–570.
2. Couse JF, Korach KS (1999) Estrogen receptor null mice: what have we learned
and where will they lead us? Endocr Rev 20: 358–417.
3. Koehler KF, Helguero LA, Haldosen LA, Warner M, Gustafsson JA (2005)
Reflections on the discovery and significance of estrogen receptor beta. Endocr
Rev 26: 465–478.
4. McDonnell DP, Norris JD (2002) Connections and regulation of the human
estrogen receptor. Science 296: 1642–1644.
5. Peterson TJ, Karmakar S, Pace MC, Gao T, Smith CL (2007) The silencing
mediator of retinoic acid and thyroid hormone receptor (SMRT) corepressor is
required for full estrogen receptor alpha transcriptional activity. Mol Cell Biol
27: 5933–5948.
6. Hu X, Lazar MA (1999) The CoRNR motif controls the recruitment of
corepressors by nuclear hormone receptors. Nature 402: 93–96.
7. Voegel JJ, Heine MJ, Tini M, Vivat V, Chambon P, et al. (1998) The
coactivator TIF2 contains three nuclear receptor-binding motifs and mediates
transactivation through CBP binding-dependent and -independent pathways.
Embo J 17: 507–519.
8. Heery DM, Kalkhoven E, Hoare S, Parker MG (1997) A signature motif in
transcriptional co-activators mediates binding to nuclear receptors. Nature 387:
733–736.
9. Rosenfeld MG, Lunyak VV, Glass CK (2006) Sensors and signals: a coactivator/
corepressor/epigenetic code for integrating signal-dependent programs of
transcriptional response. Genes Dev 20: 1405–1428.
10. Xu J, Li Q (2003) Review of the in vivo functions of the p160 steroid receptor
coactivator family. Mol Endocrinol 17: 1681–1692.
11. Kamei Y, Xu L, Heinzel T, Torchia J, Kurokawa R, et al. (1996) A CBP
integrator complex mediates transcriptional activation and AP-1 inhibition by
nuclear receptors. Cell 85: 403–414.
12. Yao TP, Oh SP, Fuchs M, Zhou ND, Ch’ng LE, et al. (1998) Gene dosage-
dependent embryonic development and proliferation defects in mice lacking the
transcriptional integrator p300. Cell 93: 361–372.
13. Zhang X, Krutchinsky A, Fukuda A, Chen W, Yamamura S, et al. (2005)
MED1/TRAP220 exists predominantly in a TRAP/Mediator subpopulation
enriched in RNA polymerase II and is required for ER-mediated transcription.
Mol Cell 19: 89–100.
14. Xu W (2005) Nuclear receptor coactivators: the key to unlock chromatin.
Biochem Cell Biol 83: 418–428.
15. Chen YH, Kim JH, Stallcup MR (2005) GAC63, a GRIP1-dependent nuclear
receptor coactivator. Mol Cell Biol 25: 5965–5972.
16. Kim JH, Li H, Stallcup MR (2003) CoCoA, a nuclear receptor coactivator
which acts through an N-terminal activation domain of p160 coactivators. Mol
Cell 12: 1537–1549.
17. Yuan J, Chen J (2011) The role of the human SWI5-MEI5 complex in
homologous recombination repair. J Biol Chem 286: 9888–9893.
18. Akamatsu Y, Jasin M (2010) Role for the mammalian Swi5-Sfr1 complex in
DNA strand break repair through homologous recombination. PLoS Genet 6:
e1001160.
19. Kokabu Y, Murayama Y, Kuwabara N, Oroguchi T, Hashimoto H, et al. (2011)
Fission yeast Swi5-Sfr1 protein complex, an activator of Rad51 recombinase,
forms an extremely elongated dogleg-shaped structure. J Biol Chem 286: 43569–
43576.
20. Bromberg J, Darnell JE Jr (2000) The role of STATs in transcriptional control
and their impact on cellular function. Oncogene 19: 2468–2473.
21. Burkhard P, Stetefeld J, Strelkov SV (2001) Coiled coils: a highly versatile
protein folding motif. Trends Cell Biol 11: 82–88.
22. Gruber M, Lupas AN (2003) Historical review: another 50th anniversary–new
periodicities in coiled coils. Trends Biochem Sci 28: 679–685.
23. Shang Y, Hu X, DiRenzo J, Lazar MA, Brown M (2000) Cofactor dynamics and
sufficiency in estrogen receptor-regulated transcription. Cell 103: 843–852.
24. Fernandes I, Bastien Y, Wai T, Nygard K, Lin R, et al. (2003) Ligand-dependent
nuclear receptor corepressor LCoR functions by histone deacetylase-dependent
and -independent mechanisms. Mol Cell 11: 139–150.
25. Park SE, Xu J, Frolova A, Liao L, O’Malley BW, et al. (2005) Genetic deletion
of the repressor of estrogen receptor activity (REA) enhances the response to
estrogen in target tissues in vivo. Mol Cell Biol 25: 1989–1999.
26. Mussi P, Liao L, Park SE, Ciana P, Maggi A, et al. (2006) Haploinsufficiency of
the corepressor of estrogen receptor activity (REA) enhances estrogen receptor
function in the mammary gland. Proc Natl Acad Sci U S A 103: 16716–16721.
27. Kurtev V, Margueron R, Kroboth K, Ogris E, Cavailles V, et al. (2004)
Transcriptional regulation by the repressor of estrogen receptor activity via
recruitment of histone deacetylases. J Biol Chem 279: 24834–24843.
28. Montano MM, Ekena K, Delage-Mourroux R, Chang W, Martini P, et al.
(1999) An estrogen receptor-selective coregulator that potentiates the effective-
ness of antiestrogens and represses the activity of estrogens. Proc Natl Acad
Sci U S A 96: 6947–6952.
29. Williamson LM, Lees-Miller SP (2011) Estrogen receptor alpha-mediated
transcription induces cell cycle-dependent DNA double-strand breaks. Carci-
nogenesis 32: 279–285.
30. Ju BG, Rosenfeld MG (2006) A breaking strategy for topoisomerase IIbeta/
PARP-1-dependent regulated transcription. Cell Cycle 5: 2557–2560.
31. Yan C, Whitsett JA (1997) Protein kinase A activation of the surfactant protein B
gene is mediated by phosphorylation of thyroid transcription factor 1. J Biol
Chem 272: 17327–17332.
32. Link KA, Burd CJ, Williams E, Marshall T, Rosson G, et al. (2005) BAF57
governs androgen receptor action and androgen-dependent proliferation
through SWI/SNF. Mol Cell Biol 25: 2200–2215.
33. Takeshita A, Koibuchi N, Oka J, Taguchi M, Shishiba Y, et al. (2001)
Bisphenol-A, an environmental estrogen, activates the human orphan nuclear
receptor, steroid and xenobiotic receptor-mediated transcription.
Eur J Endocrinol 145: 513–517.
34. Singleton DW, Feng Y, Burd CJ, Khan SA (2003) Nongenomic activity and
subsequent c-fos induction by estrogen receptor ligands are not sufficient to
promote deoxyribonucleic acid synthesis in human endometrial adenocarcinoma
cells. Endocrinology 144: 121–128.
35. Martini PG, Delage-Mourroux R, Kraichely DM, Katzenellenbogen BS (2000)
Prothymosin alpha selectively enhances estrogen receptor transcriptional activity
by interacting with a repressor of estrogen receptor activity. Mol Cell Biol 20:
6224–6232.
36. Stengel KR, Dean JL, Seeley SL, Mayhew CN, Knudsen ES (2008) RB status
governs differential sensitivity to cytotoxic and molecularly-targeted therapeutic
agents. Cell Cycle 7: 1095–1103.
SFR1 Interacts with Estrogen Receptor Alpha
PLOS ONE | www.plosone.org 9 July 2013 | Volume 8 | Issue 7 | e68075
